The efficacy of an antibody discovery campaign, diagnostic assay, or vaccine-oriented research program depends strongly on the design and quality of the antigen used at the beginning. Sequence selection, epitope exposure, host expression system, purification strategy, folding status, modification profile, and analytical release criteria can all determine whether downstream immunization, screening, or assay development generates meaningful results.
Creative Biolabs provides end-to-end veterinary antigen generation services built around the biology of the target species and the intended downstream application. Our scientists can design and produce recombinant proteins, custom peptides, plasmid DNA, and IVT mRNA antigens for companion-animal and broader veterinary R&D programs, with quality packages that support antibody discovery, ELISA development, functional screening, and preclinical research planning.
We offer a comprehensive suite of antigen generation services tailored for veterinary applications. Each platform is selected according to antigen structure, species relevance, immunogenicity needs, purity requirements, and the downstream use of the reagent.
High-quality DNA and mRNA synthesis services tailored for veterinary immunogen design. Coding sequences can be optimized for relevant expression systems and delivered as plasmids or IVT mRNA for DNA immunization, mRNA vaccine research, or in vivo antibody discovery workflows.
Explore DNA/RNA synthesis >Recombinant protein production in bacterial, mammalian, or insect cell systems for immunization, screening, and assay development. Each antigen is designed, expressed, purified, and quality-checked to support proper folding, purity, and functional relevance.
Explore recombinant expression >Custom veterinary peptide synthesis with options for modification, labeling, and carrier conjugation. Peptides are suitable for targeting defined linear epitopes, raising epitope-specific antibodies, and rapidly supporting focused assay or screening programs.
Explore peptide synthesis >Our animal antigen generation service process is designed for clarity, collaboration, and efficient project movement. The workflow can be adapted for recombinant protein, peptide, DNA, or RNA antigen projects.
There is no universal antigen format. A full-length protein may be appropriate for conformational epitopes, while a peptide, DNA construct, or mRNA format may better serve a focused epitope, rapid screening, or genetic immunization strategy.
| Antigen Format | Best-Fit Use | Design Focus | Decision-Oriented Output |
|---|---|---|---|
| Recombinant protein | Antibody discovery, ELISA antigen, immunogen generation, functional screening | Domain boundaries, host system, solubility, folding, tags, purification method | Purified antigen with purity, identity, concentration, and application notes |
| Synthetic peptide | Linear epitope targeting, blocking studies, peptide ELISA, rapid immunogen development | Epitope accessibility, hydrophilicity, carrier conjugation, terminal modification | High-purity peptide with optional conjugate, MS data, and handling guidance |
| Plasmid DNA | Genetic immunization, construct screening, antigen expression studies | Codon usage, signal peptide, promoter compatibility, insert verification | Sequence-confirmed construct suitable for planned immunization or expression work |
| IVT mRNA | mRNA antigen research, rapid expression, vaccine-oriented exploratory studies | Template design, UTR strategy, capping, poly(A), integrity, and storage | mRNA material with analytical release information for research use |
Our scientists can recommend an antigen format, production platform, and QC package after reviewing your species, target biology, assay needs, and timeline.
A study in Frontiers in Veterinary Science described recombinant expression and characterization of the canine circovirus capsid protein as an antigen for diagnostic assay development. The figure presents SDS-PAGE results from induced and non-induced bacterial cultures, soluble and insoluble fractions, and purified recombinant capsid protein, showing how expression behavior and purification quality were assessed before downstream use.
This evidence is relevant to veterinary antigen projects because it connects antigen sequence selection, host expression, solubility evaluation, purification, and identity-oriented QC with later ELISA and antibody-based assay work. Similar considerations guide Creative Biolabs' recombinant veterinary antigen expression, DNA/RNA synthesis, peptide synthesis, purification, and customized QC services for animal-health discovery and assay-development programs.
Creative Biolabs supports antigen projects with platform flexibility, species-aware design, and QC packages shaped around downstream R&D decisions.
Antigens are planned around target species, biology, and downstream use.
Protein, peptide, DNA, and RNA routes are available.
Bioinformatics and epitope strategy guide construct selection.
Identity, purity, and project-specific QC support decisions.